Immediate Impact
59 standout
Citing Papers
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
2025 Standout
Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)
2025 Standout
Works of Howland E. Crosswell being referenced
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma
2018
Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy
2014
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Howland E. Crosswell | 181 | 59 | 211 | 116 | 22 | 333 | |
| Kevin Imrie | 140 | 61 | 151 | 59 | 16 | 328 | |
| Antonella Ferrari | 98 | 115 | 188 | 114 | 18 | 347 | |
| F Cavalli | 133 | 64 | 158 | 38 | 38 | 304 | |
| Rafael Carrión | 165 | 63 | 235 | 42 | 20 | 367 | |
| Y. Ishigatsubo | 123 | 97 | 155 | 53 | 21 | 293 | |
| Gottfried Doelken | 171 | 66 | 174 | 75 | 15 | 290 | |
| Uta Brunnberg | 125 | 57 | 115 | 62 | 23 | 327 | |
| T. K. Saikia | 92 | 43 | 149 | 71 | 19 | 326 | |
| Musleh S. Tarawneh | 106 | 29 | 124 | 32 | 21 | 300 | |
| Lisa Musick | 190 | 52 | 181 | 25 | 27 | 338 |
All Works
Login with ORCID to disown or claim papers
Loading papers...